NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis $1.40 -0.14 (-9.09%) Closing price 11/20/2026 03:47 PM EasternExtended Trading$1.46 +0.06 (+3.93%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Xenetic Biosciences Stock (NASDAQ:XBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xenetic Biosciences alerts:Sign Up Key Stats Today's Range$1.25▼$1.5850-Day Range$1.40▼$4.3352-Week Range$1.25▼$4.94Volume21,760 shsAverage Volume23,559 shsMarket Capitalization$3.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.AI Generated. May Contain Errors. Read More Xenetic Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreXBIO MarketRank™: 0.2918888577 of 5 starsXenetic Biosciences scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXenetic Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXenetic Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Xenetic Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.75% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 1.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 237.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Xenetic Biosciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by Institutions15.12% of the stock of Xenetic Biosciences is held by institutions.Read more about Xenetic Biosciences' insider trading history. Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XBIO Stock News HeadlinesContrasting Xenetic Biosciences (XBIO) and Its PeersNovember 20 at 4:00 AM | americanbankingnews.comXenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell ResistanceNovember 4, 2026 | finance.yahoo.comUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.November 22 at 1:00 AM | Paradigm Press (Ad)Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in ...October 15, 2026 | finance.yahoo.comXenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused PipelineSeptember 17, 2026 | rttnews.comXenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NETSeptember 16, 2026 | es.finance.yahoo.comXenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stakeSeptember 16, 2026 | msn.comXenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks TranscriptSeptember 16, 2026 | seekingalpha.comSee More Headlines XBIO Stock Analysis - Frequently Asked Questions How have XBIO shares performed this year? Xenetic Biosciences' stock was trading at $2.17 at the start of the year. Since then, XBIO shares have decreased by 35.5% and is now trading at $1.40. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences, Inc. (NASDAQ:XBIO) posted its earnings results on Thursday, November, 12th. The company reported ($0.72) earnings per share for the quarter. The company earned $725.26 thousand during the quarter. Xenetic Biosciences had a negative net margin of 123.72% and a negative trailing twelve-month return on equity of 58.97%. When did Xenetic Biosciences' stock split? Xenetic Biosciences shares reverse split on Monday, May 15th 2023.The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include NIO (NIO), FuelCell Energy (FCEL), Plug Power (PLUG), SNDL (SNDL), AMC Entertainment (AMC), Ideanomics (IDEX) and NVIDIA (NVDA). Company Calendar Last Earnings11/12/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 XBIO's financial health is in the Red zone, according to TradeSmith. XBIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XBIO CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees2Year Founded2011Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.68 million Net Margins-123.72% Pretax Margin-123.69% Return on Equity-58.97% Return on Assets-49.54% Debt Debt-to-Equity RatioN/A Current Ratio3.15 Quick Ratio3.15 Sales & Book Value Annual Sales$2.98 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.74Miscellaneous Outstanding Shares2,340,000Free Float2,165,000Market Cap$3.28 million OptionableNot Optionable Beta2.36 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:XBIO) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored“IMPERIUM”: The #1 investment of 2027Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.